glp 1 discovery gila monster We wouldn't have Ozempic without monsters — their hunger-regulating venom inspired weight-loss drugs How Gila Monster Venom &

The PNA mouse may be the best animal model of polycystic ovary syndrome

How AOD-9604 Peptide Works Human growth hormone influences fat metabolism

Learn more about Diabetes Management

By Product: Ozempic dominates, Tirzepatide products growing fastest Ozempic (semaglutide 0.5mg/1mg/2mg weekly subcutaneous injection) dominated the GLP-1 receptor agonist market with approximately 35.12% market share in 2025, driven by its combination of robust clinical efficacy data, early market entry, broad diabetes label, established prescriber relationships, and expanded off-label use for weight management before Wegovy's commercial scale-up

Long-term wellness, bone strength, and ongoing anti-aging benefits may continue with appropriate cycling and monitoring